TrialCancer chemotherapy and pharmacology2020

Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors.

Geraldine O 'Sullivan Coyne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.